Literature DB >> 33712667

Patient individual phase gating for stereotactic radiation therapy of early stage non-small cell lung cancer (NSCLC).

K M Kraus1, M Oechsner2, J J Wilkens2, K A Kessel2,3,4, S Münch2, S E Combs2,3,4.   

Abstract

Stereotactic body radiotherapy (SBRT) applies high doses and requires advanced techniques to spare surrounding tissue in the presence of organ motion. In this work patient individual phase gating is investigated. We studied peripheral and central primary lung tumors. The internal target volume (ITV) was defined including different numbers of phases picked from a 4D Computed tomography (CT) defining the gating window (gw). Planning target volume (PTV) reductions depending on the gw were analyzed. A treatment plan was calculated on a reference phase CT (rCT) and the dose for each breathing phase was calculated and accumulated on the rCT. We compared the dosimetric results with the dose calculated when all breathing phases were included for ITV definition. GWs including 1 to 10 breathing phases were analyzed. We found PTV reductions up to 38.4%. The mean reduction of the lung volume receiving 20 Gy due to gating was found to be 25.7% for peripheral tumors and 16.7% for central tumors. Gating considerably reduced esophageal doses. However, we found that simple reduction of the gw does not necessarily influence the dose in a clinically relevant range. Thus, we suggest a patient individual definition of the breathing phases included within the gw.

Entities:  

Mesh:

Year:  2021        PMID: 33712667      PMCID: PMC7955128          DOI: 10.1038/s41598-021-85031-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer.

Authors:  Gregory M M Videtic; Chandana A Reddy; Lisa Sorenson
Journal:  Support Care Cancer       Date:  2012-06-02       Impact factor: 3.603

2.  A study on the dosimetric accuracy of treatment planning for stereotactic body radiation therapy of lung cancer using average and maximum intensity projection images.

Authors:  Long Huang; Kwangyoul Park; Thomas Boike; Pam Lee; Lech Papiez; Timothy Solberg; Chuxiong Ding; Robert D Timmerman
Journal:  Radiother Oncol       Date:  2010-04-27       Impact factor: 6.280

3.  American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy.

Authors:  Louis Potters; Brian Kavanagh; James M Galvin; James M Hevezi; Nora A Janjan; David A Larson; Minesh P Mehta; Samuel Ryu; Michael Steinberg; Robert Timmerman; James S Welsh; Seth A Rosenthal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-01       Impact factor: 7.038

4.  Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer.

Authors:  René W M Underberg; Frank J Lagerwaard; Ben J Slotman; Johan P Cuijpers; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

5.  Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  David S Ettinger; Douglas E Wood; Dara L Aisner; Wallace Akerley; Jessica Bauman; Lucian R Chirieac; Thomas A D'Amico; Malcolm M DeCamp; Thomas J Dilling; Michael Dobelbower; Robert C Doebele; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Leah J Leisch; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2017-04       Impact factor: 11.908

6.  Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".

Authors:  Joe Y Chang; Qiao-Qiao Li; Qing-Yong Xu; Pamela K Allen; Neal Rebueno; Daniel R Gomez; Peter Balter; Ritsuko Komaki; Reza Mehran; Stephen G Swisher; Jack A Roth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

7.  Tracking, gating, free-breathing, which technique to use for lung stereotactic treatments? A dosimetric comparison.

Authors:  Jessica Prunaretty; Pierre Boisselier; Norbert Aillères; Olivier Riou; Sebastien Simeon; Ludovic Bedos; David Azria; Pascal Fenoglietto
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-24

8.  Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study.

Authors:  Coen W Hurkmans; Johan P Cuijpers; Frank J Lagerwaard; Joachim Widder; Uulke A van der Heide; Danny Schuring; Suresh Senan
Journal:  Radiat Oncol       Date:  2009-01-12       Impact factor: 3.481

9.  Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?

Authors:  Donna H Murrell; Joanna M Laba; Abigail Erickson; Barbara Millman; David A Palma; Alexander V Louie
Journal:  Radiat Oncol       Date:  2018-04-02       Impact factor: 3.481

10.  Dosimetric Implications of Number of Breathing Phases Used in the Definition of Internal Target Volume [ITV] in the Treatment of Non-Small Cell Lung Cancers Using Stereotactic Body Radiation Therapy (SBRT).

Authors:  Von Darius Heard; Eftekhar Rajab Bolookat; Bradley Rauschenbach; Kate Martin; Jorge Gomez; Anurag K Singh; Harish Malhotra
Journal:  Ann Lung Cancer       Date:  2019-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.